https://scholars.lib.ntu.edu.tw/handle/123456789/628843
標題: | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON | 作者: | Hartmaier, Ryan J Markovets, Aleksandra A Ahn, Myung Ju Sequist, Lecia V Han, Ji-Youn Cho, Byoung Chul Yu, Helena A Kim, Sang-We CHIH-HSIN YANG Lee, Jong-Seok Su, Wu-Chou Kowalski, Dariusz M Orlov, Sergey Ren, Song Frewer, Paul Ou, Xiaoling Cross, Darren A E Kurian, Nisha Cantarini, Mireille Jänne, Pasi A |
關鍵字: | TYROSINE KINASE INHIBITORS; PHASE-II PLATFORM; PATIENT; NSCLC; CRIZOTINIB; VOLITINIB; THERAPY; DISEASE; AZD9291; POTENT | 公開日期: | 9-一月-2023 | 出版社: | AMER ASSOC CANCER RESEARCH | 卷: | 13 | 期: | 1 | 起(迄)頁: | 98 | 來源出版物: | Cancer discovery | 摘要: | MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib TATTON (NCT02143466) analysis (Part B, n = 138/Part D, n = 42) assessing oral savolitinib 600 mg/300 mg once daily (q.d.) + osimertinib 80 mg q.d. in patients with MET-amplified, EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) and progression on prior EGFR-TKI. An acceptable safety profile was observed. In Parts B and D, respectively, objective response rates were 33% to 67% and 62%, and median progression-free survival (PFS) was 5.5 to 11.1 months and 9.0 months. Increased antitumor activity may occur with MET copy number ≥10. EGFRm circulating tumor DNA clearance on treatment predicted longer PFS in patients with detectable baseline ctDNA, while acquired resistance mechanisms to osimertinib + savolitinib were mediated by MET, EGFR, or KRAS alterations. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628843 | ISSN: | 2159-8274 | DOI: | 10.1158/2159-8290.CD-22-0586 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。